Abstract：Objective: To investigate the protective effect of clofibrate on chronic renal failure (CRF) rats based on the PPARα/CPT1A pathway. Methods: Sprague-Dawley male rats were randomly assigned into sham surgery (Sham) group,CRF group,clofibrate group,and clofibrate+GW6471 (PPARα inhibitor) group,with 12 rats in each group.A CRF rat model was constructed using 5/6 nephrectomy.After 8 weeks of corresponding drug intervention,the levels of serum SCr,BUN and blood lipid were detected.biochemical method was applied to detect the activities of SOD,GSH-Px,and content of MDA in renal tissue.ELISA method was applied to detect the levels of tumor necrosis factor-α (TNF-α),interleukin-1β,and IL-6 in renal tissue.HE staining was applied to observe pathological changes in kidney tissue.Masson staining was applied to observe renal interstitial fibrosis injury.Western blot was applied to detect the expression of PPARα and CPT1A proteins in the kidneys. Results: Treatment with clofibrate decreased the levels of SCr,BUN,TC,TG,LDL-C in serum,the content of MDA,levels of TNF-α,IL-1β,IL-6,and proportion of interstitial fibrosis area in renal tissue (P<0.05),increased the level of HDL-C in serum,the activities of SOD and GSH-Px,and levels of PPARα and CPT1A proteins in renal tissue (P<0.05).GW6471 could weaken the protective effect of clofibrate on renal injury in CRF rats (P<0.05). Conclusion: Clofibrate may improve lipid metabolism,inhibit oxidative stress and inflammatory response,and alleviate renal injury in CRF rats by activating the PPARα/CPT1A pathway.
刘丽霞, 张路, 齐姗姗. 基于PPARα/CPT1A通路探讨氯贝特对慢性肾衰竭大鼠的保护作用[J]. 河北医学, 2025, 31(4): 597-602.
LIU Lixia, ZHANG Lu, QI Shanshan. Exploring the Protective Effect of Clofibrate on Chronic Renal Failure Rats Based on the PPARα/CPT1A Pathway. HeBei Med, 2025, 31(4): 597-602.
[1] Olsen E,van Galen G.Chronic renal failure-causes,clinical findings,treatments and prognosis[J].Vet Clin North Am Equine Pract,2022,38(1):25-46. [2] 应俊,方和敬,周韩菁,等.海昆肾喜胶囊联合贝那普利治疗慢性肾衰竭疗效及对肾功能和氧化应激指标的影响[J].中华中医药学刊,2024,42(8):208-211. [3] Wang M,Wang L,Zhou L,et al.Shen-Shuai-Ⅱ-Recipe inhibits tubular inflammation by PPARα-mediated fatty acid oxidation to attenuate fibroblast activation in fibrotic kidneys[J].Phytomedicine,2024(126):155450. [4] Muroya Y,Ito O.Effect of clofibrate on fatty acid metabolism in the kidney of puromycin-induced nephrotic rats[J].Clin Exp Nephrol,2016,20(6):862-870. [5] Baek J,He C,Afshinnia F,et al.Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease[J].Nat Rev Nephrol,2022,18(1):38-55. [6] Singh J,Jain A,Bhamra R,et al.The mechanistic role of different mediators in the pathophysiology of nephropathy:a review[J].Curr Drug Targets,2023,24(2):104-117. [7] Liu B,Hu Y,Tian D,et al.Assessing the effects of tempol on renal fibrosis,inflammation,and oxidative stress in a high-salt diet combined with 5/6 nephrectomy rat model:utilizing oxidized albumin as a biomarker[J].BMC Nephrol,2024,25(1):64. [8] Sucajtys-Szulc E,Debska-Slizien A,Rutkowski B,et al.Hepatocyte nuclear factor-1α increases fibrinogen gene expression in liver and plasma fibrinogen concentration in rats with experimental chronic renal failure[J].Int Mol Sci,2023,24(6):5733. [9] Tan E,Gao Z,Wang Q,et al.Berberine ameliorates renal interstitial inflammation and fibrosis in mice with unilateral ureteral obstruction[J].Basic Clin Pharmacol Toxicol,2023,133(6):757-769. [10] Ibarra-Lara L,Sanchez-Aguilar M,Del Valle-Mondragon L,et al.Clofibrate improves myocardial ischemia-induced damage through regulation of renin-angiotensin system and favours a pro-vasodilator profile in left ventricle[J].Pharmacol Sci,2020,144(4):218-228.
2025, Vol. 31 
冀公网安备13080202000786号